Covalent Modifiers

OCTOBER 12, 2024

Eric M. Merten and John D. Sears and Tina M. Leisner and P. Brian Hardy and Anirban Ghoshal and Mohammad Anwar Hossain and Kesatebrhan Haile Asressu and Peter J. Brown and Edwin G. Tse and Michael A. Stashko and Kelin Li and Jacqueline L. Norris-Drouin and Laura E. Herring and Angie L. Mordant and Thomas S. Webb and Christine A. Mills and Natalie K.

Virus 64

Virus Biochemical Assays FDA Approval FDA 64

New Drug Approvals

OCTOBER 12, 2024

VALILTRAMIPROSATE 1034190-08-3 (S)-3-(2-Amino-3-methylbutanamido)propane-1-sulfonic acid BLU8499 WHO 11912 Molecular Weight 238.30 Formula C 8 H 18 N 2 O 4 S CAS No. 1034190-08-3 ALZ-801 Synonyms: valiltramiprosate, NRM-8499, homotaurine prodrug, 3-APS This is a prodrug of homotaurine, a modified amino acid previously developed under the names tramiprosate and Alzhemed.

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

Drugs.com

OCTOBER 12, 2024

SATURDAY, Oct. 12, 2024 -- You've broken a hip and rehabilitation is part of the way back to mobility, or your partner has suffered a stroke and needs help re-learning certain skills.These scenarios play out every day for Americans, and.

52

52

New Drug Approvals

OCTOBER 12, 2024

VICATERTIDE 1251838-01-3 L-Leucyl-L-glutaminyl-L-valyl-L-valyl-L-tyrosyl-L-leucyl-L-histidine C 42 H 66 N 10 O 10 L-Histidine, L-leucyl-L-glutaminyl-L-valyl-L-valyl-L-tyrosyl-L-leucyl- (ACI) 871.04 SB-01, HY-P5542, CS-0887146 (2 S )-2-[[(2 S )-2-[[(2 S )-2-[[(2 S )-2-[[(2 S )-2-[[(2 S )-5-amino-2-[[(2 S )-2-amino-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(1 H -imidazol-5-yl)propano

62

62

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials